{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"0.000"},{"groupId":"OG001","spread":"0.000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"199.798","value":"315.979"},{"groupId":"OG001","spread":"267.128","value":"302.642"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Cycle 1 Day 1; 2 hours post dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"229.948","value":"441.978"},{"groupId":"OG001","spread":"263.634","value":"510.154"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Cycle 2 Day 1; Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"370.140","value":"764.500"},{"groupId":"OG001","spread":"508.607","value":"884.185"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 2; Day 1; 2 hours post dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Blood samples were collected by sparse PK sampling to analyze plasma concentration of Niraparib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Analysis Set. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 2 Hours post-dose on Cycle 1 Day 1; Pre-dose and 2 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)","title":"Phase 2: Plasma Concentrations of Niraparib","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}